Research Study

Comparison of Aripiprazole Versus Risperidone on Brain Morphology Using MRI
Principal Investigator 
Alasdair Barr

Overview

Body Locations and Systems 
Bipolar Disorder
Diagnosis and Therapy 
MRI Scans
Disorders and Conditions 
Bipolar Disorder
ClinicalTrials.gov# 
NCT02334904
Status 
Recruiting
Study Start/End 
Jul 8, 2014 to Jan 1, 2018
Locations 
UBC Hospital, Vancouver Community
Name/Title 
Delrae Fawcett, Research Assistant
Phone 
604-875-2000 ext.6115
Email Address 
delrae.fawcett@ubc.ca
Purpose of Study 

Significant changes in brain morphology are observed in people with first-episode psychosis. Studies have shown that total brain volume and particular brain structures are decreased in people with psychosis disorders. Recent evidence suggests that some atypical antipsychotic drugs can maintain or increase brain volumes. Thus, we plan to use MRI scans to measure changes in brain morphology in subjects recently diagnosed with bipolar or psychosis disorders who are taking the atypical antipsychotic drugs aripiprazole or risperidone. Secondary objectives include taking blood samples for fasting metabolic indices and neuropsychiatric measures for comparisons between drug treatments.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.